Skip to main content
. 2024 Dec 12;272(1):54. doi: 10.1007/s00415-024-12829-9

Table 2.

Clinical and demographic characteristics of SCA3 mutation carriers for each haplotype of the expanded allele (bp987 and bp1118)

Haplotype, expanded allele bp987–bp1118 Sign p value
Cytosine–Adenine Guanine–Cytosine Cytosine–Cytosine Guanine–Adenine
N 189 66 15 10 n.a
N male/female (%) 96/93 (50.8/49.2) 30/36 (45.5/54.5) 8/7 (53.3/46.7) 4/6 (40/60) 0.801

Age at baseline

 Mean [SD]

48.14 [12.41] 48.23 [14.24] 45.83 [12.72] 51.87 [16.14] 0.732

CAG repeats longer allele

 Median [IQR]

69.00 [66.00, 71.00] 70.00 [66.00, 71.75] 70.00 [67.50, 72.00] 67.50 [66.25, 70.00] 0.613

Age of onset

 Mean [SD]

40.75 [9.36] 40.64 [10.84] 36.67 [6.77] 36.20 [13.16] 0.232

SARA sum score

 Median [IQR]

9.50 [4.00, 16.00] 9.00 [4.00, 17.25] 13.50 [8.00, 23.75] 20.00 [15.62, 22.25] * 0.013

SARA sum score annual progression

 Median [IQR]

0.86 [0.00, 1.98] 0.56 [− 0.38, 2.19] 2.76 [0.52, 4.07] 0.66 [0.28, 1.67] 0.213

INAS count

 Median [IQR]

4.00 [2.00, 7.00] 5.00 [3.00, 6.75] 4.00 [3.50, 5.50] 8.00 [5.50, 9.00] 0.093

Disease duration at baseline, in years4

 Median [IQR]

8.03 [3.40, 13.84] 8.36 [2.98, 13.52] 10.87 [5.37, 18.77] 17.50 [12.05, 21.99] 0.593

n.a. non applicable, sign. Significance, IQR interquatile range, SD standard deviation; *p < 0.05

1Fisher-Test

2One-way Anova

3Kruskal–Wallis Test

4Disease duration is defined as the time from the age of onset (detailed description is given in the Methods section) until baseline visit, in years